⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607334 | 0.73 | — | — | |
| SCHEMBL3303061 | 0.73 | — | — | |
| SCHEMBL24760609 | 0.71 | — | — | |
| SCHEMBL13158541 | 0.71 | — | — | |
| SCHEMBL7050244 | 0.70 | ALDH1A1 (0.41) | — | |
| SCHEMBL13213761 | 0.69 | CHRNA4 (0.42) | — | |
| SCHEMBL19191282 | 0.68 | CHRNA4 (0.36) | — | |
| SCHEMBL803439 | 0.68 | MEN1 (0.44) | — | |
| SCHEMBL10283737 | 0.68 | — | — | |
| SCHEMBL315415 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | claimed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | claimed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4351570-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347569-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| CN-117715893-A | Combination therapy comprising a MAT2A inhibitor and a PRMT type II inhibitor | 伊迪亚生物科学公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023086934-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TAXANE | IDEAYA BIOSCIENCES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022256808-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | IDEAYA BIOSCIENCES INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256806-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-2755952-B1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2755952-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8629166-B2 | 5-cycloalkyl- or 5-heterocyclyl-nicotinamides | HOFFMANN-LA ROCHE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |